stocks NPS Pharmaceuticals Inc

Midday movers: Apple, Netflix, Lowe's & More
1:40 PM ET Fri, 30 May 2014
Some of Friday's midday movers:
Even biotechs blame the weather
12:49 PM ET Thu, 8 May 2014
It's been a gloomy week for biotech earnings, and many have blamed their poor results on, of all things, the weather.
Midday movers: Carnival, Netlfix, Pfizer & More
3:54 PM ET Thu, 27 March 2014
Some of Tuesday's midday movers:
Lightning Round: Hertz, NPS Pharma & More
6:42 PM ET Wed, 11 Dec 2013
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
NPS Pharma CEO: Netpara will have greater potential than Gattex
2:53 PM ET Thu, 10 Oct 2013
Francois Nader, NPS Pharmaceuticals president & CEO, discusses its lead product Gattex for "short bowel syndrome," the potential for Netpara and the solid performance of its stock.
8 stocks up more than 200% year to date: Cramer
6:53 PM ET Tue, 1 Oct 2013
They’re among the best performers in the Russell 2000 and they all share something in common.
Lightning Round: Visa, Pandora & More
6:43 PM ET Mon, 30 Sept 2013
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Jim Cramer spec surges 200% in 6 months
6:53 PM ET Wed, 11 Sept 2013
Sometimes a spec stock turns out to be more right than even Cramer imagined.
NPS Pharma CEO: Do not need to raise cash
1:58 AM ET Thu, 12 Sept 2013
NPS Pharmaceuticals is a developer of orphan drugs for ultra-rare diseases, and its stock has been on a tear for 6 months. Its CEO Dr. Francois Nader discusses its latest trials and FDA approvals.
Lightning Round: US Airways, Xerox & More
7:17 PM ET Fri, 31 May 2013
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Cramer: Real Opportunity in This Drug Maker
7:11 PM ET Mon, 7 Jan 2013
"It's speculative, but I think we could have a real opportunity here," said Cramer
NPS Pharmaceuticals CEO on Gattex's FDA Approval
6:46 PM ET Mon, 7 Jan 2013
NPS Pharmaceuticals CEO Dr. Francois Nader discusses the approval of its short bowel syndrome drug Gattex, and what's next for the company.
13 Biotech Stock Predictions for 2013
8:02 AM ET Wed, 2 Jan 2013
TheStreet.com offers up 13 biotech predictions for 2013.
FDA panel votes to support NPS Pharma bowel drug
8:13 PM ET Sun, 11 Nov 2012
NEW YORK-- A Food and Drug Administration advisory panel on Tuesday recommended that the FDA approve NPS Pharmaceuticals Inc.' s experimental bowel drug Gattex. The positive recommendation from the Gastrointestinal Drugs Advisory Committee makes it more likely the FDA will approve Gattex, although does not guarantee approval.
NPS shares halted as FDA panel reviews bowel drug
7:46 PM ET Sun, 11 Nov 2012
NEW YORK-- Trading of NPS Pharmaceuticals Inc. shares was halted Tuesday as a Food and Drug Administration advisory panel began discussing NPS' experimental bowel drug Gattex. NPS will discuss Gattex with the FDA's Gastrointestinal Drugs Advisory Committee. NPS Pharmaceuticals shares trade on the Nasdaq Global Market.
NPS Pharma jumps ahead of Gattex FDA review
5:57 PM ET Sun, 11 Nov 2012
NEW YORK-- Shares of NPS Pharmaceuticals Inc. surged to their highest price in more than six years Friday as investors hope that a Food and Drug Administration advisory panel will recommend that the FDA approve NPS' bowel drug Gattex.
RESEARCH ALERT-S&P Capital IQ cuts NPS Pharmaceuticals price target
5:41 PM ET Sun, 11 Nov 2012
Oct 12- NPS Pharmaceuticals Inc:. *S&P Capital IQ cuts NPS Pharmaceuticals price target by $2 to $15;. Reuters Station users, click. 1568.
UPDATE 1-FDA staff says NPS Pharma's bowel drug needs no safety restrictions
5:39 PM ET Sun, 11 Nov 2012
*FDA staff found 3 concerns, but safety restrictions not needed. "There was, on a consensus basis, a little apprehension about what the safety questions would be and these documents make it pretty clear that the FDA is not overly concerned or views these risks as significant," McNicoll, Lewis& Vlak analyst Ed Arce said.
FDA staff says NPS Pharma's bowel drug needs no safety restrictions
5:35 PM ET Sun, 11 Nov 2012
Oct 12- U.S. drug reviewers found three serious concerns related to NPS Pharmaceuticals Inc's experimental drug for short bowel syndrome, but said they did not think the drug needed to be restricted for safety reasons, according to documents posted by the Food and Drug Administration on its website Friday.
BRIEF-NPS Pharmaceuticals shares up in premarket trade
5:33 PM ET Sun, 11 Nov 2012
NEW YORK, Oct 12- NPS Pharmaceuticals Inc:.

« First

Next » | Last »

var mps=mps||{}; mps._queue=mps._queue||{}; mps._queue.gptloaded=mps._queue.gptloaded||[]; mps._queue.gptloaded.push(function() { (mps && mps.insertAd && mps.insertAd('#dart_wrapper_badgec', 'badgec')); }); stocks NPS Pharmaceuticals Inc

stocks NPS Pharmaceuticals Inc